4-54270725-A-G
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PP2PP3BS2
The ENST00000257290.10(PDGFRA):āc.1214A>Gā(p.Tyr405Cys) variant causes a missense change. The variant allele was found at a frequency of 0.00000625 in 1,440,426 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Y405S) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000257290.10 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PDGFRA | NM_006206.6 | c.1214A>G | p.Tyr405Cys | missense_variant | 8/23 | ENST00000257290.10 | NP_006197.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PDGFRA | ENST00000257290.10 | c.1214A>G | p.Tyr405Cys | missense_variant | 8/23 | 1 | NM_006206.6 | ENSP00000257290 | P1 | |
PDGFRA | ENST00000509092.5 | n.1032A>G | non_coding_transcript_exon_variant | 7/15 | 1 | |||||
PDGFRA | ENST00000509490.5 | c.1214A>G | p.Tyr405Cys | missense_variant, NMD_transcript_variant | 8/18 | 1 | ENSP00000424218 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome AF: 0.00000625 AC: 9AN: 1440426Hom.: 0 Cov.: 26 AF XY: 0.00000557 AC XY: 4AN XY: 718212
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Polyps, multiple and recurrent inflammatory fibroid, gastrointestinal Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 13, 2024 | - - |
Gastrointestinal stromal tumor Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 04, 2023 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PDGFRA protein function. ClinVar contains an entry for this variant (Variation ID: 528600). This variant has not been reported in the literature in individuals affected with PDGFRA-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 405 of the PDGFRA protein (p.Tyr405Cys). - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 14, 2023 | The p.Y405C variant (also known as c.1214A>G), located in coding exon 7 of the PDGFRA gene, results from an A to G substitution at nucleotide position 1214. The tyrosine at codon 405 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at